T2EVOLVE Association Launches to Advance Collaboration and Innovation in Advanced Cell Therapies Across Europe
For more information, clic here
AMM-Only Project Pioneers Grant Programme 2026: Funding Innovative Research in Duchenne Muscular Dystrophy - Applications Now Open
AMM-Only Project, a Monaco-based association dedicated to advancing research in Duchenne muscular dystrophy (DMD) and related neuromuscular diseases, is pleased to announce the opening of applications for the 2026 edition of the Pioneers Grant Programme. Launched in 2025, the Pioneers Grant Programme was created to accelerate scientific discovery and the development of innovative therapeutic approaches for Duchenne muscular dystrophy and other neuromuscular disorders. The pro
Genome Engineering : Research and Applications
July 6–9, 2026 | Porto, Portugal | Sheraton Porto Hotel & Spa KEYNOTE SPEAKER Luigi Naldini, MD, PhD
MOOC on gene and gene-based cell therapies for rare diseases
Foundation For Rare Diseases (Fondation Maladies Rares, France) organises an online MOOC on gene and gene-based cell therapies for rare diseases . The course features contributions from leading U.S. and European researchers — including Alain Fischer, Heather Gray Edwards, Alessio Cantore, Zoltan Ivics, Sylvie Odent, Salima Hacein-Bey-Abina, Manuel Gonçalves, Marina Cavazzana, Allison Bradbury, Anne Galy, Chantal Pichon, Claire Booth, Jeffrey Medin , among others — as well a
In memory of Professor Claudio Bordignon
ESGCT are greatly saddened by the loss of Professor Claudio Bordignon, a pioneer in the gene therapy field, and the first President of the ESGCT.
FDA approval of LAD gene therapy
Last Thursday, the FDA approved the LAD gene therapy developed by Juan A. Bueren and Elena Almarza, in collaboration with the Adrian Thrasher team. This treatment was licensed to Rocket Pharma, who developed the clinical trial and presented it to the FDA. We believe this is terrific news for the gene therapy field and for ESGCT, as all these advances have come from ESGCT members, and the society has played a fundamental role in favouring this collaboration and in the developm
ForTra gGmbH and the SPARK-BIH team cordially invite you to their joint workshop on GCT in Frankfurt/Main
The ForTra gGmbH (the nonprofit subsidiary of the Else Kröner-Fresenius Foundation for research transfer) and the SPARK-BIH team of the National Strategy for Gene- and Cell-Based Therapies cordially invite you to their joint workshop on GCT in Frankfurt/Main. Join ForTra and the SPARK-BIH team of the National Strategy for Gene- and Cell-Based Therapies for an inspiring, forward-looking workshop on Gene and Cell therapy (GCT) – one of the most dynamic fields shaping t
Around the World: Global Seminar Series Australasia - Thursday 26 February 2026
Hosted as part of the AROUND THE WORLD SERIES in collaboration with the Coalition of International Gene Therapy Societies.
FDA approval of the Biologics License Application (BLA) for Waskyra, the first gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS).
The ESGCT would like to congratulate Fondazione Telethon and HSR-TIGET on the milestone achievement of the FDA approval of WAS ex vivo gene therapy. Please see below their statement: We are honoured to share a moment of profound significance for us, for patients, families, and the scientific community. The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Waskyra , the first gene therapy for the treatment of Wiskott-Aldrich
2025-SEVILLE
The 32nd ESGCT Annual Congress took place in collaboration with SETGYC from 7-10 October 2025 at Fibes in Seville. Congress delegates can log in to their online registration portal to access the Congress abstract book, online programme, and Certificate of Attendance. Login here > Abstracts published by Human Gene Therapy will be available soon. Event Statistics (Click to enlarge) We are very grateful for the support of all our sponsors and partners.
